Monthly Prescribing Reference

Incruse Ellipta Inhaler Approved for COPD

Incruse Ellipta Inhaler Approved for COPD GlaxoSmithKline announced that the FDA has approved Incruse Ellipta (umeclidinium) inhaler for the long-term, once-daily, maintenance treatment of airflow ...
Monthly Prescribing Reference

Incruse Ellipta

Umeclidinium 62.5mcg; per inhalation; dry pwd for oral inhalation; contains lactose. Incruse Ellipta should be stored at room temperature between 68°-77° F (20°-25° C); excursions permitted from ...
FiercePharma

GSK receives approval for Incruse™ Ellipta® (umeclidinium) in the US for the treatment of COPD

LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse™ Ellipta ® (umeclidinium) as an ...
FiercePharma

GSK receives EU marketing authorisation for Incruse® (umeclidinium) for the treatment of COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse® (umeclidinium) as a once-daily, maintenance bronchodilator treatment ...
Washington Times

FDA OKs Glaxo’s inhaler, first one to combine 3 medicines

TRENTON, N.J. (AP) - The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday ...
Yahoo Finance

GSK and Theravance Announce Positive Data From Two Studies Evaluating the Efficacy and Safety of Incruse(TM) Ellipta(R) When Added to Relvar(R)/Breo(R) Ellipta(R) in Patients ...

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 11, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from ...
Business Wire

Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

Trelegy Ellipta is the first once-daily single inhaler triple therapy approved in the US for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease ...
News Medical

Incruse Ellipta

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Do not use if you have ever had an allergic reaction to INCRUSE ...
Seattle Times

FDA OKs Glaxo’s inhaler, first one to combine 3 medicines

TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday ...
WRAL TechWire

FDA OKs Glaxo’s inhaler which is first one to combine 3 medicines

The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA earlier this week approved sales ...